Skip to content
contact@indiamedicine.orgLogin / Register
IMSDA
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
Search for:
Menu Close
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us

Knowledge

  1. Home>
  2. News>
  3. Knowledge>
  4. Page 5

How to Verify Generic Medicine Quality: A Practical Buyer’s Checklist for India

  • Post published:September 8, 2026
  • Post category:Knowledge

Buying generic medicines in India can save significant money — but quality varies widely between manufacturers. According to the World Health Organization (WHO), generic medicines should be bioequivalent to their…

Continue Reading How to Verify Generic Medicine Quality: A Practical Buyer’s Checklist for India

Understanding India’s NDCT Rules 2026 Amendments: A Guide for Pharma Buyers

  • Post published:September 6, 2026
  • Post category:Knowledge

India's pharmaceutical regulatory landscape is undergoing significant transformation. In January 2026, the Government of India notified key amendments to the New Drugs & Clinical Trials (NDCT) Rules, introducing changes that…

Continue Reading Understanding India’s NDCT Rules 2026 Amendments: A Guide for Pharma Buyers

WHO-GMP Certification for Indian Generic Medicines: A 2026 Buyer’s Complete Guide

  • Post published:September 3, 2026
  • Post category:Knowledge

When you are sourcing generic medicines from India — whether for a hospital formulary, a government tender, or personal use — the WHO-GMP (World Health Organization Good Manufacturing Practice) certification…

Continue Reading WHO-GMP Certification for Indian Generic Medicines: A 2026 Buyer’s Complete Guide

CDSCO Mandates Pharma Companies to Maintain Adverse Event Reporting Systems

  • Post published:September 1, 2026
  • Post category:Knowledge

In June 2026, India's Central Drugs Standard Control Organisation (CDSCO) issued a directive requiring all pharmaceutical manufacturers in India to maintain a robust pharmacovigilance system for reporting adverse events (AEs)…

Continue Reading CDSCO Mandates Pharma Companies to Maintain Adverse Event Reporting Systems
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 69
  • Go to the next page

Recent Posts

  • How India Trains Drug Inspectors: WHO Fellowship & GMP Checks
    November 17, 2026/
    0 Comments
  • India’s First Midazolam Nasal Spray: CDSCO Nod, 5-Year Shield
    November 16, 2026/
    0 Comments
  • How to Challenge Medicine Overcharging in India: DPCO Display Rules
    November 15, 2026/
    0 Comments

Follow Us

IMSDA

Recent Posts

  • How India Trains Drug Inspectors: WHO Fellowship & GMP Checks
  • India’s First Midazolam Nasal Spray: CDSCO Nod, 5-Year Shield
  • How to Challenge Medicine Overcharging in India: DPCO Display Rules
  • NPPA Extends Knee Implant Price Cap: What Buyers Must Check in 2027
  • How to Read a CDSCO Clinical Trial Approval: A 2026 Buyer’s Guide

Contact Info

  • If you want to touch more medicine sales and distribution resources, you could contact us, or join us.
  • Address:2nd Floor, Bhavani CHS, Dadar West, Mumbai, 400028, Maharashtra.
  • Phone:+91 8048111688
  • Email:contact@indiamedicine.orgOpens in your application
  • Website:https://indiamedicine.org/
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
© Copyright All Right Reserve